Aging Populations And Regulatory Tailwinds Will Expand Specialty Therapies
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
25 Jul 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
CA$8.00
64.1% undervalued intrinsic discount21 Aug
CA$2.87
1Y
18.1%7D
-2.7%